Retraction Retraction dated 2025-05-12
Click to view Retraction: https://doi.org/10.1038/s41598-025-00263-4
-
Authors
Shen, Abra H.
Borrelli, Mimi R.
Adem, Sandeep
Deleon, Nestor M. Diaz
Patel, Ronak A.
Mascharak, Shamik
Yen, Sara J.
Sun, Blake Y.
Taylor, Walter L. IV
Januszyk, Michael
Nguyen, Dung H.
Momeni, Arash
Gurtner, Geoffrey C.
Longaker, Michael T.
Wan, Derrick C.
-
Funding
Funding for this research was provided by:
Sarnoff Cardiovascular Research Foundation
Plastic Surgery Research Foundation
California Institute for Regenerative Medicine
National Institutes of Health (U01 HL099776)
National Institutes of Health (DE027346)
National Institutes of Health,United States (R01 GM116892)
Steinhart/Reed Fund
Gunn/Olivier Research Fund
- License Information
-
More Information
Article History
Received: 15 February 2020
Accepted: 6 July 2020
First Online: 23 July 2020
Change Date: 12 May 2025
Change Type: Correction
Change Details: This article has been retracted. Please see the Retraction Notice for more detail:
Change Details: https://doi.org/10.1038/s41598-025-00263-4
Competing interests
: G.C.G. and M.T.L. hold equity in Tautona Group who supplied the deferoxamine patch. G.C.G. holds a patent for transdermal delivery of deferoxamine (#2010/0092546). G.C.G., M.T.L., and D.C.W. hold a patent for application of deferoxamine to treat irradiated tissue (#2018/050626). The other authors declare no conflict of interests.
